Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Molecular Templates stock

Learn how to easily invest in Molecular Templates stock.

Molecular Templates Inc is a biotechnology business based in the US. Molecular Templates shares (MTEM) are listed on the NASDAQ and all prices are listed in US Dollars. Molecular Templates employs 262 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Molecular Templates

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MTEM – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Molecular Templates stock price (NASDAQ: MTEM)

Use our graph to track the performance of MTEM stocks over time.

Molecular Templates shares at a glance

Information last updated 2022-01-24.
Latest market close$3.17
52-week range$3.01 - $15.19
50-day moving average $4.05
200-day moving average $6.57
Wall St. target price$11.57
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.88

Buy Molecular Templates shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
M1 Finance
Free 1-year trial of M1 Plus
when you sign up for M1 Finance
Invest in your favorite stocks or in curated portfolios with automatic rebalancing.
SoFi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stash Invest
Stocks, ETFs
$1 per month
Add at least $5 to your Invest account
Stash is more than an investment app. You’ll have access to tools that can help you become a confident investor.
Stocks, ETFs, Cryptocurrency
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $300, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Molecular Templates stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Molecular Templates price performance over time

Historical closes compared with the close of $3.17 from 2022-01-25

1 week (2022-01-15) N/A
1 month (2021-12-22) N/A
3 months (2021-10-26) -42.57%
6 months (2021-07-26) -55.16%
1 year (2021-01-26) -72.27%
2 years (2020-01-24) -76.61%
3 years (2019-01-25) 4.31
5 years (2017-01-26) 524.02%

Molecular Templates financials

Revenue TTM $24.2 million
Gross profit TTM $-74,120,000
Return on assets TTM -31.21%
Return on equity TTM -129.3%
Profit margin 0%
Book value $1.28
Market capitalisation $183.6 million

TTM: trailing 12 months

Molecular Templates share dividends

We're not expecting Molecular Templates to pay a dividend over the next 12 months.

Have Molecular Templates's shares ever split?

Molecular Templates's shares were split on a 1:11 basis on 1 August 2017. So if you had owned 11 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Molecular Templates shares – just the quantity. However, indirectly, the new 1000% higher share price could have impacted the market appetite for Molecular Templates shares which in turn could have impacted Molecular Templates's share price.

Molecular Templates share price volatility

Over the last 12 months, Molecular Templates's shares have ranged in value from as little as $3.01 up to $15.19. A popular way to gauge a stock's volatility is its "beta".

MTEM.US volatility(beta: 1.03)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Molecular Templates's is 1.028. This would suggest that Molecular Templates's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Molecular Templates overview

Molecular Templates, Inc. , a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. Its proprietary drug platform technology is engineered toxin bodies (ETBs). The company's lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed and refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. It also develops MT-4019, engineered toxin body targeting CD38; TAK-169 targeting CD38 is in Phase I clinical trial; MT-5111 targeting HER2 is in Phase I clinical trial; and MT-6402 with antigen seeding targeting PD-L1. The company has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma; and a strategic research collaboration with Vertex Pharmaceuticals Incorporated to discover and develop novel targeted biologic therapies for applications outside of oncology; and Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc.

Frequently asked questions

What percentage of Molecular Templates is owned by insiders or institutions?
Currently 27.487% of Molecular Templates shares are held by insiders and 85.418% by institutions.
How many people work for Molecular Templates?
Latest data suggests 262 work at Molecular Templates.
When does the fiscal year end for Molecular Templates?
Molecular Templates's fiscal year ends in December.
Where is Molecular Templates based?
Molecular Templates's address is: 9301 Amberglen Boulevard, Austin, TX, United States, 78729
What is Molecular Templates's ISIN number?
Molecular Templates's international securities identification number is: US6085501095
What is Molecular Templates's CUSIP number?
Molecular Templates's Committee on Uniform Securities Identification Procedures number is: 608550109

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site